::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::

CODEN : IAJPBB
issn 2349-7750

News Updates Latest Volumes: COSMOS IMPACT FACTOR (2018)- 4.153, GLOBAL IMPACT FACTOR(2014) - 0.384, (2015) - 0.437, Indo American Journal of Pharmaceutical Sciences,

ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

COMPARISON OF NEW DIRECTLY ACTING ANTIVIRALS WITH PEGINTERFERON IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF CHRONIC HCV INFECTION IN CHRONIC KIDNEY PATIENTS BOTH PRE-DIALYSIS AND ON DIALYSIS

AUTHORS:

Dr Kashif Hussain, Dr Tehseen Fatima, Dr.Saman

ABSTRACT:

The HCV infection has a unique association with chronic kidney disease (CKD). The study was conducted from 20 January 2018 to 20 January 2019. The patients from different hospitals of Lahore were included, in which men and women with age range of 18 to 80 years were present. The medication was administered as 400mg/100mg tables once daily for 12 weeks. The assessments were conducted at screening, baseline, weeks 2, 4, 8, and 12 for on treatment and weeks 4 and 12 after treatment. Out of 100 patients, 97 (97%) achieved SVR 12 after 12 weeks of treatment. Majority (80%) of the participants experienced adverse effects; however, these were mild or moderate in severity. The findings of present study recommend use of both types of medications used, that is, peginterferon with sofosbuvir and Declatasvir/Ledipasvir with sofosbuvir for HCV infected patients with CKD. These medications are well tolerated, effective and safe for treatment of 12 weeks.